# US 11,993,649 B2 · Antibodies against MFAP4 > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,993,649 B2 - Document ID: US11993649B2 - Status: Granted - Kind: B2 - Application number: 16/760,490 - Filed: 2018-11-01 - Published: 2023-02-16 - Granted: 2024-05-28 - Earliest claimed: 2017-11-01 - Assignees: Syddansk Universitet - Applicants: Syddansk Universitet - Inventors: Grith Lykke Sørensen; Anders Schlosser; Uffe Holmskov - Web page: https://patentgrep.com/patent/US11993649B2 ## CPC - C07K 16/28: against receptors, cell surface antigens or cell surface determinants - C07K 16/18: against material from animals or humans - A61K 2039/505: {comprising antibodies} - C07K 2317/56: variable (Fv) region, i.e. VH and/or VL - C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to antibodies, including humanized antibodies that bind human Microfibrillar-associated protein 4 (MFAP4). The invention also relates to uses of such antibodies. ## Claims ### Claim 1 A protein ligand, comprising: (a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 3, or a sequence having at least 90% sequence identity to SEQ ID NO: 3; and (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4, or a sequence having at least 90% sequence identity to SEQ ID NO: 4; the protein ligand comprising: (a) a light chain variable region comprising a CDR 1 region according to SEQ ID NO: 9, a CDR 2 region according to SEQ ID NO: 10, and a CDR 3 region according to SEQ ID NO: 11; and (b) a heavy chain variable region comprising a CDR 1 region according to SEQ ID NO: 12, a CDR 2 region according to SEQ ID NO: 13, and a CDR 3 region according to SEQ ID NO: 14. ### Claim 2 (depends on 1) The protein ligand according to claim 1, comprising: (a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 3; and (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4. ### Claim 3 (depends on 1) The protein ligand according to claim 1, wherein the ligand is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, an antibody, wherein the heavy chain and the light chain are connected by a flexible linker, an Fv molecule, an antigen binding fragment, a Fab fragment, a Fab′ fragment, a F(ab′)2 molecule, a humanized antibody, and a chimeric antibody. ### Claim 4 (depends on 1) The protein ligand according to claim 1, wherein the ligand is a F(ab′)2 molecule. ### Claim 5 (depends on 1) The protein ligand according to claim 1, wherein the antibody is humanized. ### Claim 6 (depends on 1) The protein ligand according to claim 1, wherein the antibody is a humanized monoclonal antibody. ### Claim 7 (depends on 1) The protein ligand according to claim 1, coupled to a detectable label or a substance having toxic or therapeutic activity. ### Claim 8 (depends on 1) The protein ligand according to claim 1, having KD value to rhMFAP4 below 1*10−7. ### Claim 9 (depends on 1) The protein ligand according to claim 1, being primarily in a monomeric form. ### Claim 10 (depends on 1) The protein ligand according to claim 1, wherein the ligand does not bind to the RGD-integrin interaction sequence in the rhMFAP4 N-terminal domain. ### Claim 11 (depends on 1) A vector encoding the ligand according to claim 1. ### Claim 12 (depends on 1) A cell expressing the ligand according to claim 1. ### Claim 13 (depends on 11) A cell comprising the vector according to claim 11. ### Claim 14 (depends on 1) A composition comprising the ligand according to claim 1, and one or more physiologically acceptable carriers, excipients and/or diluents. ### Claim 15 (depends on 1) A method of treating vascular proliferative diseases and/or related disorder in a mammal comprising administering the protein ligand according to claim 1 to a mammal in need of such treatment, wherein the vascular proliferative diseases and/or related disorder are characterized by pathological neovascularization, vascular leakage, inflammation, or fibrosis of the eye. ### Claim 16 (depends on 15) The method according to claim 15, wherein the disorder characterized by pathological neovascularization in the eye is selected from the group consisting of age related macular degeneration (AMD), including geographic athropy and proliferative AMD, retinal vein occlusion, retinopathy, hypertensive retinopathy, vitreomacular traction, and diabetic retinopathy (DR), including proliferative DR and diabetic macular edema. ### Claim 17 (depends on 15) The method according to claim 15, wherein the vascular proliferative diseases and/or related disorders are cancers or other malignancies.